Design Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview

Design Therapeutics

08/11/2024 16:03

* Design Therapeutics Inc  DSGN.OQ   DSGN.O  is expected
to show
no change in quarterly revenue when it reports  results  for the
period ending December 31 2024
    * 
    * ​LSEG's mean analyst estimate for Design Therapeutics Inc
is for
a loss of 27 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Design
Therapeutics Inc is $5.00​, below​ its last closing price
of $5.79. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.22       -0.24      -0.23     Beat    5.5
 Jun. 30 0001  -0.21       -0.23      -0.21     Beat    10
 Jan. 1 0001   -0.25       -0.26      -0.20     Beat    24.1​
 Dec. 31 2023              -0.31      -0.21     Beat    32.2
 ​​Sep.        -0.38       -0.41      -0.28     Beat    31.5
 30 2023                                                
 Jun. 30 2023  -0.39       -0.40      -0.36     Beat    9.4​
 Mar. 31 2023  -0.36       -0.36      -0.35     Beat    2.6
 Dec. 31 2022  -0.38       -0.34      -0.31     Beat    9.9
 This summary was machine generated November 8 at 16:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)